注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
通过基金全球化的资产配置和组合管理,实现组合资产的分散化投资,在降低组合波动性的同时,实现基金资产的最大增值。
名称 | 标题 | 任期 | 至 |
---|---|---|---|
Lei Yun | - | 2024 | now |
Shicong Wang | - | 2024 | now |
Liang Huang | - | 2009 | 2024 |
背景介紹 | n.a | ||
guofeng ye | - | 2017 | 2018 |
Qing Cai | - | 2015 | 2017 |
Fu Lin Zhu | - | 2014 | 2014 |
背景介紹 | N/A | ||
Yang Qu | - | 2013 | 2014 |
背景介紹 | N.A | ||
Ming Yu Xu | - | 2010 | 2012 |
背景介紹 | N/A | ||
Hao Dong Li | co-Founder | 2008 | 2010 |
背景介紹 | Li joined FBRIM in 2002. Prior to that he was a scientist on the founding team at Human Genome Sciences (“HGSI”). After leaving HGSI in 1996, he co-founded Shenyang Sunshine Pharmaceuticals, the largest biotechnology company in China with $30M in sales. He received 18 biotechnology U.S. patents. Li performed his post-doctoral fellowship at Harvard Medical School under Dr. Bill Haseltine in the area of virology and infectious diseases. | ||
Wei Hong Xie | - | 2007 | 2010 |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核